Unionized workers at Samsung Biologics ended their historic five-day general strike on Wednesday and shifted to a work-to-rule campaign to sustain pressure over pay demands. A one-on-one meeting with management is set for later Wednesday, followed by a three-way session with the labor ministry on Friday, amid ongoing disagreements.
Following the walkout that began May 1—marking the biotech firm's first strike since 2011—about 2,800 of 4,000 unionized workers in Incheon returned to their posts. The action, which followed a partial strike last month causing 150 billion won (US$101.5 million) in losses, now continues via strict adherence to safety rules during work-to-rule.
Divisions persist over the union's call for a 14 percent pay hike, 30 million won (US$20,390) one-time incentives, and 20 percent profit-sharing bonuses, against the company's 6.2 percent offer. Additional union proposals include boosted incentives and a labor-management fund for community and vendor sharing. "No consensus has been reached," a union representative stated.
Talks resumed Monday without agreement. "We will engage sincerely in the two rounds of talks this week," the company said. The series of negotiations builds on 13 prior rounds and government mediation.
